| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802603201017 | 260320101 | FUZEON PS.INJ.SOL 90MG/ML 60VIALS PD.FOR INJ + 60VIALS SOLV+60SYR.x3ML+60SYR.x1ML+180 ΤΟΛΥΠΙΑ ΕΜΠΟΤ. ΜΕ ΟΙΝΟΠΝΕΥΜΑ | 1239.23 | 1257.82 | 1389.96 |
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide is a biomimetic peptide that was rationally designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion.
3.8 +/- 0.6 hrs
* 5.5 ± 1.1 L
* 24.8 +/- 4.1 mL/h/kg [HIV-1 infected adult and pediatric subjects following a 90-mg single SC dose of enfuvirtide] * 30.6 +/- 10.6 mL/h/kg [Following 90-mg twice daily dosing of FUZEON SC in combination with other antiretroviral agents in HIV-1 infected subjects] * 40 +/- 17 mL/h/kg [pediatric patients in the presence of concomitant medications including antiretroviral agents receiving the 2 mg/kg twice daily dose]